Intiva BioPharma Inc. Appoints Courtney Clark as Director and Chair of the Company's Audit Committee
August 15, 2018 at 11:16 am
Share
On August 10, 2018, Intiva BioPharma Inc. increased the number of directors on its Board to four and appointed Courtney Clark to fill the vacancy created by that increase. Ms. Clark is currently a director of Kanativa Inc., the
Ontario, Canada parent of the company, and has more than 15 years of corporate finance expertise. She
founded Aspen Peak Advisors, a marketing and investment banking firm in 2010, after having been an analyst and investment banker with TerraNova Capital Partners specializing in global emerging growth companies, primarily in the energy, technology, and medical device spaces. Ms. Clark will serve as the chair of the company's Audit Committee.
Nexien BioPharma, Inc. is engaged in pre-clinical and drug development activities for certain pharmaceutical formulations that include cannabinoids. The Company is focused on developing and commercializing United States Food and Drug Administration (FDA)-compliant cannabinoid pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders and medical conditions. Its flagship research and development programs are focused on advancing formulations that have the potential to improve the treatment outcomes of certain convulsive disorders and neuromuscular disorders, which includes the treatment of myotonic dystrophy. The Company's wholly owned subsidiaries include Intiva BioPharma Inc., NexN Inc. (NexN) and NexDM Inc.
NEXIEN BIOPHARMA, INC. 
